The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection
Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 e...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14657
- Acceso en línea:
- https://doi.org/10.1016/j.jacbts.2020.10.003
http://hdl.handle.net/20.500.12010/14657
- Palabra clave:
- COVID-19
SARS-CoV-2
ACE2
Alpha5beta1 integrin
ATN-161
Therapeutic
Host-cell entry
Viral spike protein
Receptor binding domain
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)